CARGO Therapeutics,

CARGO Therapeutics,

Company profile

About

Cargo Therapeutics (NASDAQ:CRGX) is a clinical-stage biopharmaceutical company developing innovative medicines for hematologic malignancies, which are cancers of the blood and blood-forming tissues. Their lead candidate, rocatribor, is a targeted small molecule inhibitor currently in Phase 2 clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cargo Therapeutics aims to leverage its scientific expertise and collaborative partnerships to bring life-changing therapies to patients with these challenging diseases.

Snapshot

2019Year founded

118Employees

California, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of CARGO Therapeutics,

Rocatribor: A targeted small molecule inhibitor currently in Phase 2 clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
CAR-T cell therapy: A personalized cellular therapy approach that involves engineering a patient's T cells to recognize and attack cancer cells.
CAR-NK cell therapy: Another form of cellular therapy using natural killer (NK) cells, which have the innate ability to recognize and kill cancer cells.
Bispecific T cell engagers (BiTEs): A type of immunotherapy that uses molecules to link T cells to cancer cells, triggering the immune system to destroy the cancer cells.
TCR-T cell therapy: A cellular therapy approach that uses T cells engineered with a specific T cell receptor (TCR) to recognize and target cancer cells.
Gene editing therapies: A new frontier in cancer treatment that uses technologies like CRISPR to modify genes and potentially cure cancer.